Zentalis Pharmaceuticals (Nasdaq: ZNTL) granted non-qualified stock options to purchase an aggregate of 269,000 shares of common stock to four newly hired employees on September 1, 2026. According to Zentalis, the awards were issued under its 2022 Employment Inducement Incentive Award Plan in line with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $3.71 per share, equal to the closing price on the grant date, and a 10-year term. Vesting occurs over four years: 25% on the first anniversary of the vesting commencement date, then the remaining 75% in equal monthly installments over the following three years, subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
ZNTL’s 90-day insider record showed Net Buying, with 4,335,000 shares bought and 0 shares sold. That...
Analysis
ZNTL’s 90-day insider record showed Net Buying, with 4,335,000 shares bought and 0 shares sold. That ownership activity adds context to the grant, while continued-service vesting remains a relevant risk.
Key Figures
Options granted:269,000 sharesNew employees:Four employeesExercise price:$3.71 per share+5 more
8 metrics
Options granted269,000 sharesAggregate grant to four newly hired employees
New employeesFour employeesRecipients of the inducement grants
Exercise price$3.71 per shareEqual to the closing price on the grant date
Option term10 yearsTerm of the stock options
Vesting periodFour yearsTotal vesting schedule
Initial vesting25%Vests on the first anniversary
Remaining vesting75%Vests in equal monthly installments thereafter
Remaining vesting periodThree yearsPeriod for monthly vesting installments
Options covering 84,000 shares went to two newly hired employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent offering and earnings announcements were followed by negative reactions, while the prior inducement-grant announcement was followed by a positive reaction.
A Wee1 inhibitor is a drug that blocks the Wee1 protein, which normally acts like a safety brake that pauses damaged cells before they divide. By removing that brake, cancer cells with DNA damage are forced into division and often die, making the approach useful for targeting tumors. Investors track Wee1 inhibitors because their clinical trial success, safety profile and use with other therapies can greatly affect a biotechnology company's value.
non-qualified stock optionsfinancial
"granted non-qualified stock options to purchase an aggregate"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 269,000 shares of the Company’s common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $3.71 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant.The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
What inducement stock options did Zentalis Pharmaceuticals (ZNTL) grant on September 1, 2026?
Zentalis granted non-qualified stock options for an aggregate of 269,000 shares of common stock to four newly hired employees. According to Zentalis, these options were issued under the 2022 Employment Inducement Incentive Award Plan as a material inducement for joining the company.
What is the exercise price of the September 1, 2026 ZNTL inducement options?
The inducement stock options have an exercise price of $3.71 per share. According to Zentalis, this price equals the closing price of its common stock on The Nasdaq Global Market on the September 1, 2026 grant date, aligning the awards with then-current market value.
How do the Zentalis (ZNTL) inducement stock options granted in September 2026 vest?
The inducement options vest over four years. According to Zentalis, 25% vests on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the following three years, contingent on the employee’s continued service.
What is the term of the ZNTL inducement stock options granted to new employees?
The inducement stock options have a 10-year term from the grant date. According to Zentalis, employees may exercise vested options during this period, subject to plan terms and continued service requirements that govern ongoing vesting and post-termination exercise rights.
Under which plan were Zentalis (ZNTL) September 2026 inducement grants issued?
The grants were issued under the 2022 Employment Inducement Incentive Award Plan. According to Zentalis, this plan is used exclusively for equity awards to individuals not previously employed, as a material inducement to employment, consistent with Nasdaq Listing Rule 5635(c)(4) requirements.
How many new employees received ZNTL inducement stock options on September 1, 2026?
Four newly hired employees received the inducement stock options. According to Zentalis, these individuals were granted non-qualified options covering an aggregate of 269,000 shares, with awards structured as employment inducements under Nasdaq Listing Rule 5635(c)(4) and subject to the plan’s vesting conditions.
